ClinicalTrials.gg
CompletedNCT03395184Updated Oct 30, 2024Results posted

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

A Phase 2 interventional study of PF-06651600 Placebo and PF-06651600 in Crohn's Disease, sponsored by Pfizer. Completed at 195 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.

Enrollment
4th of 11
244 · median 180
Started
2018
with 1 other
Phase 2
9 of 17
none open now
Registered
13th of 17
by date

Among the 17 studies in Crohn Disease by Pfizer, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2018, is one of 9 in phase 2, and was the 13th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Crohn Disease by Pfizer as a file.
02

Study summary

The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for 12 weeks) dosed once daily during an induction period of 12 weeks, followed by an open label extension period at doses of 50 mg and 30 mg of PF 06651600 and PF 06700841, respectively, for 52 weeks.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and/or female subjects 18 years to 75 years of age
  2. Documented diagnosis of ileal, ileocolonic, or colonic CD with a minimum disease duration of 3 months, as determined by endoscopic and histopathology assessment.
  3. Endoscopic confirmation of active disease with total SES CD total score of at least 7. For isolated ileal disease, SES CD total score should be at least 4.
  4. An average daily liquid/soft stool frequency (SF) greater than or equal to 2.5 or daily abdominal pain (AP) greater than or equal to 2.0.
  5. Must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for CD:

    •; (azathioprine [AZA], 6 MP, or methotrexate [MTX]); Anti TNF inhibitors (infliximab, adalimumab,certolizumab); Anti integrin inhibitors (eg, vedolizumab); Anti IL 12/23 inhibitor (ustekinumab).

  6. Subjects currently receiving the following treatment for CD are eligible providing they have been on stable doses as described below:

    • Oral corticosteroids (prednisone or equivalent up to 25 mg/day; budesonide up to 9 mg/day). Stable dose for at least 2 weeks prior to baseline. If oral corticosteroids have been recently discontinued, they must have been stopped at least 2 weeks prior to baseline. Decreases in steroid use due to AEs are allowed.
    • Oral 5 ASA or sulfasalazine are allowed providing that the dose is stable for at least 4 weeks prior to baseline.
    • Crohn's disease related antibiotics are allowed providing that the dose is stable for at least 4 weeks prior to baseline. If antibiotics are stopped prior to baseline, they must be discontinued at least 4 days prior to baseline.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, diverticular disease, ulcerative colitis (UC), or clinical findings suggestive of UC.
  2. Presence of active (draining) fistulae or intra abdominal or perineal abscesses.
  3. Strictures with obstructive symptoms.
  4. Short bowel syndrome.
  5. History of bowel perforation requiring surgical intervention within the past 12 months.
  6. Previous bowel surgery resulting in an existing stoma. Subjects who have a j pouch are excluded, as a j pouch can result in a stoma.
  7. History of bowel surgery within 6 months prior to baseline.
  8. Subjects displaying clinical signs of fulminant colitis or toxic megacolon.
  9. Subjects with primary sclerosing cholangitis.
  10. Subjects with evidence of colonic adenomas, dysplasia or neoplasia.
  11. Abnormal findings on the chest x ray film such as presence of tuberculosis (TB), general infections, heart failure, or .
  12. Any history of either untreated or inadequately treated latent or active TB infection, current treatment for active or latent TB infection or evidence of currently active TB by chest x ray, residing with or frequent close contact with individual(s) with active TB.
  13. Subjects receiving the following therapies within the time period described below or expected to receive any of these therapies during the study period:

    1. >9 mg/day of oral budesonide or >25 mg/day of prednisone or equivalent oral systemic dose within 2 weeks prior to baseline.
    2. IV, IM (parenteral), or topical (rectal) treatment of 5 ASA or corticosteroid enemas/suppositories within 2 weeks prior to baseline.
    3. Azathioprine, 6 mercaptopurine, or methotrexate within 2 weeks prior to baseline.
    4. Anti TNF inhibitors (or biosimilars thereof) as described below:

      • Infliximab within 8 weeks prior to baseline;
      • Adalimumab within 8 weeks prior to baseline;
      • Certolizumab within 8 weeks prior to baseline;
    5. Anti integrin inhibitors (eg, vedolizumab) within 8 weeks prior to baseline.
    6. Ustekinumab within 8 weeks prior to baseline.
    7. Interferon therapy within 8 weeks prior to baseline.
    8. Subjects with prior treatment with lymphocyte depleting agents/therapies within 1 year prior to baseline (eg, CamPath[alemtuzumab], alkylating agents [eg, cyclophosphamide or chlorambucil], total lymphoid irradiation, etc).
    9. Subjects who have received rituximab or other selective B lymphocyte depleting agents within 1 year prior to baseline.
    10. Subjects previously receiving leukocyte apheresis, including selective lymphocyte, monocyte, or granulocyte apheresis, or plasma exchange within 6 months prior to baseline.
    11. Other marketed or biologics with immunomodulatory properties within 3 months prior to baseline.
    12. Subjects who have received other JAK inhibitors within 3 months prior to baseline.
    13. Subjects who have not responded to or have been intolerant of other JAK inhibitors.
    14. Other procedures(s) or product(s), such as immunosuppressants used in transplantation (eg, mycophenolate mofetil, cyclosporine, rapamycin, or tacrolimus) or live (attenuated) vaccine within 30 days prior to baseline.

      1. Subjects with history of thrombotic event(s), including deep venous thrombosis (DVT), and known inherited conditions that predispose to hypercoagulability.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    PF-06700841 or placebo

    Drug: Placebo PF-06700841 · Drug: PF-06700841

  • Experimental
    PF-06651600 or placebo

    Drug: PF-06651600 Placebo · Drug: PF-06651600

Interventions

  • DrugPF-06651600 Placebo

    12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks

  • 200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks

  • DrugPlacebo PF-06700841

    12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks

  • 60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period

    SES CD50 was defined as 50% improvement from baseline in SES-CD. Baseline was defined as last measurement prior to first dosing on Day 1. Following bowel segments were used for calculating SES-CD scores: Ileum, right colon(C), transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

    Time frame: Week 12

  2. Number of Participants With Laboratory Test Abnormalities During OLE Period

    Pre-specified criteria for lab abnormalities included- hematology: hemoglobin(Hb), erythrocytes (ery),hematocrit:\<0.8\*lower limit of normal(LLN);reticulocytes: \<0.5\*LLN, \>1.5\*upper limit of normal(ULN); ery mean corpuscular(EMC) volume: \<0.9\*ULN, \>1.11\*ULN;EMC Hb: \<0.9\*LLN; platelets:\>1.75\*ULN; leukocytes(10\^9/L): \<0.6\*LLN,\>1.5\*ULN;lymphocyte,neutrophil(10\^9/L):\<0.8\*LLN,\>1.2\*ULN;basophil,eosinophil,monocyte(10\^9/L):\>1.2\*ULN;activated partial thromboplastin time (sec): \>1.1\*ULN. Chemistry: bilirubin(mg/dL),aspartate aminotransferase(AT),alanine AT(units per litre)\>3.0\*ULN; protein, albumin(g/dL):\<0.8\*LLN; creatinine, triglycerides (mg/dL):\>1.3\*ULN; urate(mg/dL):\>1.2\*ULN, potassium (mEq/L):\<0.9\*LLN; calcium (mg/dL): \<0.9\*LLN,\>1.1\*ULN. Urinalysis: pH\>8;urine,glucose,protein(mg/dl); ketones, nitrite, urine Hb(scalar):\>=1. Number of participants with any lab abnormality meeting pre-specified criteria are reported.

    Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)

  3. Number of Participants According to Categorization of Vital Signs During OLE Period

    Vital signs including blood pressure (diastolic blood pressure \[DBP\], systolic blood pressure \[SBP\], and pulse rate \[PR\]) were measured in a supine position using automated devices. DBP included value \< 50 (millimeter of mercury \[mmHg\]), change \>=20 (mmHg) increase and change \>=20 (mmHg) decrease; SBP: value \< 90 (mmHg), change \>= 30 (mmHg) increase and change \>= 30 (mmHg) decrease; PR: value \> 120 (beats per minute \[bpm\]).

    Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)

  4. Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During OLE Period

    Single twelve lead ECGs were obtained using an automated ECG machine after participant had rested quietly for at least 10 minutes in a supine position. QTc prolongations were defined as a QTc \>=480 milli second (msec) or an absolute change in QTc greater than (\>) 60 msec. Clinically significant ECG findings were determined by the investigator.

    Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs) During OLE Period

    An adverse event (AE) was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. An AE was considered TEAE to a given treatment if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.

    Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)

  6. Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During OLE Period

    A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event. An SAE was considered as TESAE if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.

    Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)

  7. Number of Participants With Discontinuations Due to Adverse Events During OLE Period

    An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. Discontinuations from study due to TEAEs were defined as participants with an AE record indicating the AE caused permanent discontinuation from the study but action taken with study treatment was not drug withdrawn. Permanent discontinuations from any study intervention due to TEAEs were defined as participants with an AE record indicating that action taken with study treatment was drug withdrawn. In this outcome measure number of participants with discontinuation from study due to AEs and permanent discontinuation from study intervention due to AEs are reported.

    Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)

Secondary outcomes

  1. Number of Participants With Laboratory Test Abnormalities During Induction Period

    Pre-specified criteria for lab abnormalities included- hematology: hemoglobin, erythrocytes, hematocrit:\<0.8\*LLN; reticulocytes: \<0.5\*LLN, \>1.5\*ULN; EMC volume: \<0.9\*ULN, \>1.11\*ULN;EMC Hb: \<0.9\*LLN; platelets:\>1.75\*ULN; leukocytes(10\^9/L): \<0.6\*LLN, \>1.5\*ULN; lymphocyte, neutrophil(10\^9/L):\<0.8\*LLN, \>1.2\*ULN; basophil, eosinophil, monocyte(10\^9/L):\>1.2\*ULN; activated partial thromboplastin time (sec): \>1.1\*ULN. Chemistry: bilirubin(mg/dL),aspartate aminotransferase(AT),alanine AT(units per litre)\>3.0\*ULN; protein, albumin(g/dL):\<0.8\*LLN; creatinine, triglycerides (mg/dL):\>1.3\*ULN; urate(mg/dL):\>1.2\*ULN, potassium (mEq/L):\<0.9\*LLN; calcium (mg/dL): \<0.9\*LLN,\>1.1\*ULN. Urinalysis: pH\>8; urine, glucose, protein(mg/dl); ketones, nitrite, urine Hb(scalar):\>=1. Number of participants with any lab abnormality meeting pre-specified criteria are reported.

    Time frame: From start of study intervention on Day 1 up to Week 12

  2. Number of Participants According to Categorization of Vital Signs During Induction Period

    Vital signs including blood pressure (diastolic blood pressure \[DBP\], systolic blood pressure \[SBP\], and pulse rate \[PR\]) were measured in a supine position using automated devices. DBP included value \< 50 (mmHg), change \>=20 (mmHg) increase and change \>=20 (mmHg) decrease; SBP: value \< 90 (mmHg), change \>= 30 (mmHg) increase and PR: value \> 120 (bpm).

    Time frame: From start of study intervention on Day 1 up to Week 12

  3. Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During Induction Period

    Single twelve lead ECGs were obtained using an automated ECG machine after participant had rested quietly for at least 10 minutes in a supine position. QTc prolongations were defined as a QTc greater than or equal to (\>=)480 milli second (msec) or an absolute change in QTc greater than (\>)60 msec. Clinically significant ECG findings were determined by the investigator.

    Time frame: From start of study intervention on Day 1 up to Week 12

  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs) During Induction Period

    An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. An AE was considered TEAE to a given treatment if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.

    Time frame: From start of study intervention on Day 1 up to Week 12

  5. Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During Induction Period

    A SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event. An SAE was considered as TESAE if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.

    Time frame: From start of study intervention on Day 1 up to Week 12

  6. Number of Participants Discontinuation Due to Adverse Events During Induction Period

    An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. Discontinuations from study due to TEAEs were defined as participants with an AE record indicating the AE caused permanent discontinuation from the study but action taken with study treatment was not drug withdrawn. Permanent discontinuations from any study intervention due to TEAEs were defined as participants with an AE record indicating that action taken with study treatment was drug withdrawn. In this outcome measure number of participants with discontinuation from study due to AEs and permanent discontinuation from study intervention due to AEs are reported.

    Time frame: From start of study intervention on Day 1 up to Week 12

  7. Number of Participants With Serious Infections During Induction Period

    Participants were monitored for development of any infection (viral, bacterial and fungal). Serious infections were treated infections that required parenteral antimicrobial therapy and were present with positive pre-treatment culture and required hospitalization for treatment/met other criteria that required the infection to be classified as SAE. An SAE was any untoward medical occurrence at any dose that: resulted in death; is life-threatening; requires inpatient hospitalization/prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity/results in congenital anomaly/birth defect. Treated infections were infections that required antimicrobial therapy by any route of administration/required any surgical intervention (e.g., incision and drainage).

    Time frame: From start of study intervention on Day 1 up to Week 12

  8. Percentage of Participants Who Achieved Clinically Meaningful Endoscopic Improvement (CMEI) (Reduction of >=3 Points From Baseline in SES-CD Score) at Week 12: Induction Period

    CMEI was defined as reduction of \>=3 points from baseline in SES-CD score as assessed by centrally read SES-CD score. Baseline: last measurement prior to first dosing on Day1. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for 4 domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on scale of 0-3, higher scores indicated more severe condition. Presence of ulcers score: 0=none,1=small ulcer: (0.1-0.5cm),2=Large ulcer(0.5-2cm),3=very large ulcer(\>2cm); ulcerated surface score: 0=none,1=\<10%,2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

    Time frame: Week 12

  9. Mean Change From Baseline in SES-CD Score at Week 12: Induction Period

    Mean change from baseline in SES-CD score at Week 12 analyzed using analysis of covariance(ANCOVA)model with treatment,baseline disease activity/extent as factors, baseline SES CD score as covariate. Baseline=last measurement prior to first dosing on Day 1. Following bowel segments used for calculating SES-CD scores: Ileum,right C,transverse C,left C,rectum. Each segment assessed for four domains:presence of ulcers, ulcerated surface, affected surface,presence of narrowing, each score on a scale of 0-3,higher scores=more severe condition. Presence of ulcers score:0=none,1=small ulcer:(0.1-0.5cm),2=large ulcer(0.5-2cm),3=very large ulcer(\>2 cm);ulcerated surface score:0=none,1=\<10%,2=10-30%,3=\>30%;affected surface score:0=unaffected segment,1=\<50%, 2=50-75%,3=\>75%;presence of narrowing score:0=none,1=single,can be passed,2=multiple can be passed,3=cannot be passed. Total SES CD score=sum of each domain score for all 5 bowel segments,range from 0 to 60,higher score =more severe disease.

    Time frame: Baseline and Week 12

  10. Percentage of Participants Achieving >=25% Reduction in SES-CD From Baseline (SES-CD 25) at Week 12: Induction Period

    SES CD25 was defined as \>=25% improvement from baseline in SES CD. Baseline was defined as the last measurement prior to first dosing on Day 1. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

    Time frame: Week 12

  11. Percentage of Participants Achieving Endoscopic Remission (SES-CD Score of <= 2) at Week 12: Induction Period

    Endoscopic remission was defined as SES-CD score of \<= 2. Following bowel segments were used for calculating SES-CD scores: Ileum, right colon(C), transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

    Time frame: Week 12

  12. Percentage of Participants Achieving Mucosal Healing at Week 12: Induction Period

    Mucosal healing was defined as complete absence of ulcers.

    Time frame: Week 12

  13. Percentage of Participants Achieving CMEI at Week 64 Among Participants Who Achieved CMEI Response at Week 12 (Baseline of OLE Period): OLE Period

    CMEI was defined as reduction of \>=3 points from baseline as assessed by centrally read SES CD score. Baseline: last measurement prior to first dosing on Day 1 of Week 12. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on scale of 0-3, higher scores indicated more severe condition. Presence of ulcers score: 0=none,1=small ulcer: (0.1-0.5 cm),2=Large ulcer(0.5-2 cm),3=very large ulcer(\>2 cm); ulcerated surface score: 0=none,1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0-60, higher score indicating more severe disease.

    Time frame: Week 64 (Week 52 of OLE period)

  14. Percentage of Participants Achieving SES CD 25 and SES CD 50 at Week 64 Among Participants Who Achieved SES CD 25 and SES CD 50 at Week 12 (Baseline of OLE Period): OLE Period

    SES CD50 and SES CD25: 50% and 25% improvement from baseline, respectively. Baseline: last measurement prior to first dosing on Day 1 of Week 12. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 cm), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

    Time frame: Week 64 (Week 52 of OLE period)

07

Results

Posted Oct 30, 2024

Participant flow

The study consisted of a 12-weeks induction period and a 52-weeks open label extension (OLE) period. The participants who completed induction period, entered the 52-week OLE period.

Induction Period (Up to 12 Weeks)
Participant flow — Induction Period (Up to 12 Weeks)
MilestoneInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QDOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
Started7993720000
Completed6884650000
Not completed11970000
Withdrew: Adverse event6440000
Withdrew: No longer meets eligibility criteria0210000
Withdrew: Withdrawal by subject2200000
Withdrew: Lost to follow-up0100000
Withdrew: Lack of efficacy2020000
Withdrew: Other1000000
OLE Period (Up to 52 Weeks)
Participant flow — OLE Period (Up to 52 Weeks)
MilestoneInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QDOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
Started00036843264
Completed00020452134
Not completed00016391130
Withdrew: Other0000202
Withdrew: Lack of efficacy00051135
Withdrew: Lost to follow-up0000200
Withdrew: Withdrawal by subject00031138
Withdrew: No longer met eligibility criteria0001010
Withdrew: Adverse event000713415

Outcome measures

PrimaryPercentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period

SES CD50 was defined as 50% improvement from baseline in SES-CD. Baseline was defined as last measurement prior to first dosing on Day 1. Following bowel segments were used for calculating SES-CD scores: Ileum, right colon(C), transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period
Percentage of participantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period12.8 (7.1 to 19.9)27.2 (19.6 to 35.7)33.8 (25.1 to 43.1)
Statistical analysis
  • Induction Period: Placebo QD vs Induction Period: Ritlecitinib 200 mg/50 mg QD · Min risk weight method(Mehrotra-Railkar) · p = 0.0119 · Percentage risk difference: 14.3 · 90% CI 4.0 to 24.590% CI was calculated using minimum (min) risk weight method (Mehrotra-Railkar 2000)
  • Induction Period: Placebo QD vs Induction Period: Brepocitinib 60 mg QD · Min risk weight method(Mehrotra-Railkar) · p = 0.0012 · Percentage risk difference: 21.4 · 90% CI 10.0 to 32.990% CI was calculated using minimum risk weight method (Mehrotra-Railkar, 2000).
PrimaryNumber of Participants With Laboratory Test Abnormalities During OLE Period

Pre-specified criteria for lab abnormalities included- hematology: hemoglobin(Hb), erythrocytes (ery),hematocrit:\<0.8\*lower limit of normal(LLN);reticulocytes: \<0.5\*LLN, \>1.5\*upper limit of normal(ULN); ery mean corpuscular(EMC) volume: \<0.9\*ULN, \>1.11\*ULN;EMC Hb: \<0.9\*LLN; platelets:\>1.75\*ULN; leukocytes(10\^9/L): \<0.6\*LLN,\>1.5\*ULN;lymphocyte,neutrophil(10\^9/L):\<0.8\*LLN,\>1.2\*ULN;basophil,eosinophil,monocyte(10\^9/L):\>1.2\*ULN;activated partial thromboplastin time (sec): \>1.1\*ULN. Chemistry: bilirubin(mg/dL),aspartate aminotransferase(AT),alanine AT(units per litre)\>3.0\*ULN; protein, albumin(g/dL):\<0.8\*LLN; creatinine, triglycerides (mg/dL):\>1.3\*ULN; urate(mg/dL):\>1.2\*ULN, potassium (mEq/L):\<0.9\*LLN; calcium (mg/dL): \<0.9\*LLN,\>1.1\*ULN. Urinalysis: pH\>8;urine,glucose,protein(mg/dl); ketones, nitrite, urine Hb(scalar):\>=1. Number of participants with any lab abnormality meeting pre-specified criteria are reported.

Time frame:
From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities During OLE Period
ParticipantsOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
Number of Participants With Laboratory Test Abnormalities During OLE Period33762656
PrimaryNumber of Participants According to Categorization of Vital Signs During OLE Period

Vital signs including blood pressure (diastolic blood pressure \[DBP\], systolic blood pressure \[SBP\], and pulse rate \[PR\]) were measured in a supine position using automated devices. DBP included value \< 50 (millimeter of mercury \[mmHg\]), change \>=20 (mmHg) increase and change \>=20 (mmHg) decrease; SBP: value \< 90 (mmHg), change \>= 30 (mmHg) increase and change \>= 30 (mmHg) decrease; PR: value \> 120 (beats per minute \[bpm\]).

Time frame:
From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants According to Categorization of Vital Signs During OLE Period
ParticipantsOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
DBP; value < 50 (mmHg)0201
DBP; change >=20 (mmHg) increase4626
DBP; change >=20 (mmHg) decrease1438
PR; value > 120 (bpm)0100
SBP; value < 90 (mmHg)0201
SBP; change >= 30 (mmHg) increase1205
SBP; change >= 30 (mmHg) decrease3032
PrimaryNumber of Participants With Abnormal Clinically Significant Electrocardiogram Findings During OLE Period

Single twelve lead ECGs were obtained using an automated ECG machine after participant had rested quietly for at least 10 minutes in a supine position. QTc prolongations were defined as a QTc \>=480 milli second (msec) or an absolute change in QTc greater than (\>) 60 msec. Clinically significant ECG findings were determined by the investigator.

Time frame:
From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During OLE Period
ParticipantsOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During OLE Period0001
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) During OLE Period

An adverse event (AE) was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. An AE was considered TEAE to a given treatment if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.

Time frame:
From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During OLE Period
ParticipantsOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During OLE Period32582554
PrimaryNumber of Participants With Treatment Emergent Serious Adverse Events (TESAE) During OLE Period

A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event. An SAE was considered as TESAE if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.

Time frame:
From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During OLE Period
ParticipantsOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During OLE Period610516
PrimaryNumber of Participants With Discontinuations Due to Adverse Events During OLE Period

An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. Discontinuations from study due to TEAEs were defined as participants with an AE record indicating the AE caused permanent discontinuation from the study but action taken with study treatment was not drug withdrawn. Permanent discontinuations from any study intervention due to TEAEs were defined as participants with an AE record indicating that action taken with study treatment was drug withdrawn. In this outcome measure number of participants with discontinuation from study due to AEs and permanent discontinuation from study intervention due to AEs are reported.

Time frame:
From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Discontinuations Due to Adverse Events During OLE Period
ParticipantsOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
Discontinuation from study due to TEAEs0100
Permanent discontinuation from any study intervention due to TEAEs713415
SecondaryNumber of Participants With Laboratory Test Abnormalities During Induction Period

Pre-specified criteria for lab abnormalities included- hematology: hemoglobin, erythrocytes, hematocrit:\<0.8\*LLN; reticulocytes: \<0.5\*LLN, \>1.5\*ULN; EMC volume: \<0.9\*ULN, \>1.11\*ULN;EMC Hb: \<0.9\*LLN; platelets:\>1.75\*ULN; leukocytes(10\^9/L): \<0.6\*LLN, \>1.5\*ULN; lymphocyte, neutrophil(10\^9/L):\<0.8\*LLN, \>1.2\*ULN; basophil, eosinophil, monocyte(10\^9/L):\>1.2\*ULN; activated partial thromboplastin time (sec): \>1.1\*ULN. Chemistry: bilirubin(mg/dL),aspartate aminotransferase(AT),alanine AT(units per litre)\>3.0\*ULN; protein, albumin(g/dL):\<0.8\*LLN; creatinine, triglycerides (mg/dL):\>1.3\*ULN; urate(mg/dL):\>1.2\*ULN, potassium (mEq/L):\<0.9\*LLN; calcium (mg/dL): \<0.9\*LLN,\>1.1\*ULN. Urinalysis: pH\>8; urine, glucose, protein(mg/dl); ketones, nitrite, urine Hb(scalar):\>=1. Number of participants with any lab abnormality meeting pre-specified criteria are reported.

Time frame:
From start of study intervention on Day 1 up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities During Induction Period
ParticipantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Number of Participants With Laboratory Test Abnormalities During Induction Period677261
SecondaryNumber of Participants According to Categorization of Vital Signs During Induction Period

Vital signs including blood pressure (diastolic blood pressure \[DBP\], systolic blood pressure \[SBP\], and pulse rate \[PR\]) were measured in a supine position using automated devices. DBP included value \< 50 (mmHg), change \>=20 (mmHg) increase and change \>=20 (mmHg) decrease; SBP: value \< 90 (mmHg), change \>= 30 (mmHg) increase and PR: value \> 120 (bpm).

Time frame:
From start of study intervention on Day 1 up to Week 12
Reported as:
Count of participants · Participants
Number of Participants According to Categorization of Vital Signs During Induction Period
ParticipantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Diastolic blood pressure; value < 50 (mmHg)100
Diastolic blood pressure; change >=20 (mmHg) increase424
Diastolic blood pressure; change >=20 (mmHg) decrease424
Pulse rate; value > 120 (bpm)410
Systolic blood pressure; value < 90 (mmHg)030
Systolic blood pressure; change >= 30 (mmHg) increase327
Systolic blood pressure; change >= 30 (mmHg) decrease000
SecondaryNumber of Participants With Abnormal Clinically Significant Electrocardiogram Findings During Induction Period

Single twelve lead ECGs were obtained using an automated ECG machine after participant had rested quietly for at least 10 minutes in a supine position. QTc prolongations were defined as a QTc greater than or equal to (\>=)480 milli second (msec) or an absolute change in QTc greater than (\>)60 msec. Clinically significant ECG findings were determined by the investigator.

Time frame:
From start of study intervention on Day 1 up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During Induction Period
ParticipantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During Induction Period100
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) During Induction Period

An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. An AE was considered TEAE to a given treatment if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.

Time frame:
From start of study intervention on Day 1 up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During Induction Period
ParticipantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During Induction Period514649
SecondaryNumber of Participants With Treatment Emergent Serious Adverse Events (TESAE) During Induction Period

A SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event. An SAE was considered as TESAE if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.

Time frame:
From start of study intervention on Day 1 up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During Induction Period
ParticipantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During Induction Period644
SecondaryNumber of Participants Discontinuation Due to Adverse Events During Induction Period

An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. Discontinuations from study due to TEAEs were defined as participants with an AE record indicating the AE caused permanent discontinuation from the study but action taken with study treatment was not drug withdrawn. Permanent discontinuations from any study intervention due to TEAEs were defined as participants with an AE record indicating that action taken with study treatment was drug withdrawn. In this outcome measure number of participants with discontinuation from study due to AEs and permanent discontinuation from study intervention due to AEs are reported.

Time frame:
From start of study intervention on Day 1 up to Week 12
Reported as:
Count of participants · Participants
Number of Participants Discontinuation Due to Adverse Events During Induction Period
ParticipantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Discontinuations from study due to TEAEs010
Permanent discontinuations from any study intervention due to TEAEs644
SecondaryNumber of Participants With Serious Infections During Induction Period

Participants were monitored for development of any infection (viral, bacterial and fungal). Serious infections were treated infections that required parenteral antimicrobial therapy and were present with positive pre-treatment culture and required hospitalization for treatment/met other criteria that required the infection to be classified as SAE. An SAE was any untoward medical occurrence at any dose that: resulted in death; is life-threatening; requires inpatient hospitalization/prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity/results in congenital anomaly/birth defect. Treated infections were infections that required antimicrobial therapy by any route of administration/required any surgical intervention (e.g., incision and drainage).

Time frame:
From start of study intervention on Day 1 up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Serious Infections During Induction Period
ParticipantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Number of Participants With Serious Infections During Induction Period012
SecondaryPercentage of Participants Who Achieved Clinically Meaningful Endoscopic Improvement (CMEI) (Reduction of >=3 Points From Baseline in SES-CD Score) at Week 12: Induction Period

CMEI was defined as reduction of \>=3 points from baseline in SES-CD score as assessed by centrally read SES-CD score. Baseline: last measurement prior to first dosing on Day1. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for 4 domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on scale of 0-3, higher scores indicated more severe condition. Presence of ulcers score: 0=none,1=small ulcer: (0.1-0.5cm),2=Large ulcer(0.5-2cm),3=very large ulcer(\>2cm); ulcerated surface score: 0=none,1=\<10%,2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Clinically Meaningful Endoscopic Improvement (CMEI) (Reduction of >=3 Points From Baseline in SES-CD Score) at Week 12: Induction Period
Percentage of participantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Percentage of Participants Who Achieved Clinically Meaningful Endoscopic Improvement (CMEI) (Reduction of >=3 Points From Baseline in SES-CD Score) at Week 12: Induction Period29.5 (21.7 to 38.9)42.4 (34.2 to 51.5)57.7 (47.6 to 67.2)
Statistical analysis
  • Induction Period: Placebo QD vs Induction Period: Ritlecitinib 200 mg/50 mg QD · Min risk weight method(Mehrotra-Railkar) · p = 0.0390 · Percentage risk difference: 13.3 · 90% CI 1.0 to 25.790% CI was calculated using minimum risk weight method (Mehrotra-Railkar, 2000).
  • Induction Period: Placebo QD vs Induction Period: Brepocitinib 60 mg QD · Min risk weight method(Mehrotra-Railkar) · p = 0.0001 · Percentage risk difference: 29.7 · 90% CI 17.2 to 42.290% CI was calculated using minimum risk weight method (Mehrotra-Railkar, 2000).
SecondaryMean Change From Baseline in SES-CD Score at Week 12: Induction Period

Mean change from baseline in SES-CD score at Week 12 analyzed using analysis of covariance(ANCOVA)model with treatment,baseline disease activity/extent as factors, baseline SES CD score as covariate. Baseline=last measurement prior to first dosing on Day 1. Following bowel segments used for calculating SES-CD scores: Ileum,right C,transverse C,left C,rectum. Each segment assessed for four domains:presence of ulcers, ulcerated surface, affected surface,presence of narrowing, each score on a scale of 0-3,higher scores=more severe condition. Presence of ulcers score:0=none,1=small ulcer:(0.1-0.5cm),2=large ulcer(0.5-2cm),3=very large ulcer(\>2 cm);ulcerated surface score:0=none,1=\<10%,2=10-30%,3=\>30%;affected surface score:0=unaffected segment,1=\<50%, 2=50-75%,3=\>75%;presence of narrowing score:0=none,1=single,can be passed,2=multiple can be passed,3=cannot be passed. Total SES CD score=sum of each domain score for all 5 bowel segments,range from 0 to 60,higher score =more severe disease.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in SES-CD Score at Week 12: Induction Period
Units on a scaleInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Mean Change From Baseline in SES-CD Score at Week 12: Induction Period-0.1 (-1.32 to 1.12)-3.1 (-4.22 to -2.02)-5.0 (-6.36 to -3.72)
Statistical analysis
  • Induction Period: Placebo QD vs Induction Period: Ritlecitinib 200 mg/50 mg QD · ANCOVA · p = 0.0007 · Ls mean difference: -3.0 · 90% CI -4.55 to -1.48The ANCOVA model included treatment and baseline disease activity/extent as factors, and baseline SES-CD score as a covariate.
  • Induction Period: Placebo QD vs Induction Period: Brepocitinib 60 mg QD · ANCOVA · p = <.0001 · Ls mean difference: -4.9 · 90% CI -6.62 to -3.26The ANCOVA model included treatment and baseline disease activity/extent as factors, and baseline SES-CD score as a covariate.
SecondaryPercentage of Participants Achieving >=25% Reduction in SES-CD From Baseline (SES-CD 25) at Week 12: Induction Period

SES CD25 was defined as \>=25% improvement from baseline in SES CD. Baseline was defined as the last measurement prior to first dosing on Day 1. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >=25% Reduction in SES-CD From Baseline (SES-CD 25) at Week 12: Induction Period
Percentage of participantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Percentage of Participants Achieving >=25% Reduction in SES-CD From Baseline (SES-CD 25) at Week 12: Induction Period25.6 (17.7 to 34.3)39.1 (30.6 to 47.4)56.3 (46.2 to 66.4)
Statistical analysis
  • Induction Period: Placebo QD vs Induction Period: Ritlecitinib 200 mg/50 mg QD · Min risk weight method(Mehrotra-Railkar) · p = 0.0279 · Percentage risk difference: 13.9 · 90% CI 2.1 to 25.690% CI was calculated using using minimum risk weight method (Mehrotra-Railkar, 2000).
  • Induction Period: Placebo QD vs Induction Period: Brepocitinib 60 mg QD · Min risk weight method(Mehrotra-Railkar) · p = <.0001 · Percentage risk difference: 31.5 · 90% CI 19.1 to 43.990% CI was calculated using minimum risk weight method (Mehrotra-Railkar, 2000).
SecondaryPercentage of Participants Achieving Endoscopic Remission (SES-CD Score of <= 2) at Week 12: Induction Period

Endoscopic remission was defined as SES-CD score of \<= 2. Following bowel segments were used for calculating SES-CD scores: Ileum, right colon(C), transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Remission (SES-CD Score of <= 2) at Week 12: Induction Period
Percentage of participantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Percentage of Participants Achieving Endoscopic Remission (SES-CD Score of <= 2) at Week 12: Induction Period5.1 (2.3 to 11.2)7.6 (4.0 to 13.2)12.7 (7.2 to 20.8)
Statistical analysis
  • Induction Period: Placebo QD vs Induction Period: Ritlecitinib 200 mg/50 mg QD · Min risk weight method(Mehrotra-Railkar) · p = 0.2922 · Percentage risk difference: 2.5 · 90% CI -4.3 to 9.390% CI was calculated using minimum risk weight method (Mehrotra-Railkar, 2000).
  • Induction Period: Placebo QD vs Induction Period: Brepocitinib 60 mg QD · Min risk weight method(Mehrotra-Railkar) · p = 0.0449 · Percentage risk difference: 7.4 · 90% CI -0.4 to 15.290% CI was calculated using minimum risk weight method (Mehrotra-Railkar, 2000).
SecondaryPercentage of Participants Achieving Mucosal Healing at Week 12: Induction Period

Mucosal healing was defined as complete absence of ulcers.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Mucosal Healing at Week 12: Induction Period
Percentage of participantsInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QD
Percentage of Participants Achieving Mucosal Healing at Week 12: Induction Period5.1 (2.3 to 11.2)10.9 (6.1 to 17.7)16.9 (10.1 to 25.8)
Statistical analysis
  • Induction Period: Placebo QD vs Induction Period: Ritlecitinib 200 mg/50 mg QD · Min risk weight method(Mehrotra-Railkar) · p = 0.0998 · Percentage risk difference: 5.8 · 90% CI -1.6 to 13.390% CI was calculated using minimum risk weight method (Mehrotra-Railkar, 2000).
  • Induction Period: Placebo QD vs Induction Period: Brepocitinib 60 mg QD · Min risk weight method(Mehrotra-Railkar) · p = 0.0111 · Percentage risk difference: 11.8 · 90% CI 2.8 to 20.990% CI was calculated using minimum risk weight method (Mehrotra-Railkar, 2000).
SecondaryPercentage of Participants Achieving CMEI at Week 64 Among Participants Who Achieved CMEI Response at Week 12 (Baseline of OLE Period): OLE Period

CMEI was defined as reduction of \>=3 points from baseline as assessed by centrally read SES CD score. Baseline: last measurement prior to first dosing on Day 1 of Week 12. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on scale of 0-3, higher scores indicated more severe condition. Presence of ulcers score: 0=none,1=small ulcer: (0.1-0.5 cm),2=Large ulcer(0.5-2 cm),3=very large ulcer(\>2 cm); ulcerated surface score: 0=none,1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0-60, higher score indicating more severe disease.

Time frame:
Week 64 (Week 52 of OLE period)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving CMEI at Week 64 Among Participants Who Achieved CMEI Response at Week 12 (Baseline of OLE Period): OLE Period
Percentage of participantsOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
Percentage of Participants Achieving CMEI at Week 64 Among Participants Who Achieved CMEI Response at Week 12 (Baseline of OLE Period): OLE Period27.3 (10.5 to 56.4)44.1 (30.7 to 59.5)54.5 (30.2 to 80.0)42.1 (28.5 to 56.7)
SecondaryPercentage of Participants Achieving SES CD 25 and SES CD 50 at Week 64 Among Participants Who Achieved SES CD 25 and SES CD 50 at Week 12 (Baseline of OLE Period): OLE Period

SES CD50 and SES CD25: 50% and 25% improvement from baseline, respectively. Baseline: last measurement prior to first dosing on Day 1 of Week 12. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 cm), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.

Time frame:
Week 64 (Week 52 of OLE period)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving SES CD 25 and SES CD 50 at Week 64 Among Participants Who Achieved SES CD 25 and SES CD 50 at Week 12 (Baseline of OLE Period): OLE Period
Percentage of participantsOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
SES-CD 2525.0 (6.9 to 58.2)41.9 (26.9 to 57.9)54.5 (30.2 to 80.0)42.1 (28.5 to 56.7)
SES-CD 5025.0 (2.6 to 68.0)36.4 (19.6 to 55.6)50.0 (20.1 to 79.9)36.4 (19.6 to 55.6)

Adverse events

Collected over Induction Period: From start of study intervention on Day 1 up to Week 12 (for a maximum duration of 12 weeks); OLE Period: From start of study intervention in OLE period (Week 12) up to 4 weeks after last dose of study intervention on Week 64 (for a maximum duration of 56 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Period: Placebo QD0/79 (0%)6/79 (7.6%)20/79 (25.3%)
Induction Period: Ritlecitinib 200 mg/50 mg QD0/93 (0%)4/93 (4.3%)20/93 (21.5%)
Induction Period: Brepocitinib 60 mg QD0/72 (0%)4/72 (5.6%)17/72 (23.6%)
OLE Period: Placebo QD -> Ritlecitinib 50 mg QD0/36 (0%)6/36 (16.7%)29/36 (80.6%)
OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD0/84 (0%)10/84 (11.9%)34/84 (40.5%)
OLE Period: Placebo QD -> Brepocitinib 30 mg QD0/32 (0%)5/32 (15.6%)19/32 (59.4%)
OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD0/64 (0%)16/64 (25%)31/64 (48.4%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QDOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
Crohn's diseaseGastrointestinal disorders5/792/930/723/365/843/327/64
Humerus fractureInjury, poisoning and procedural complications0/790/930/720/360/841/320/64
Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/790/930/720/360/841/320/64
AnaemiaBlood and lymphatic system disorders1/790/930/721/360/840/320/64
Abdominal painGastrointestinal disorders0/790/930/721/360/840/321/64
DiarrhoeaGastrointestinal disorders0/790/930/721/360/840/320/64
Clostridium difficile colitisInfections and infestations0/790/930/721/360/840/320/64
Mesenteric abscessInfections and infestations0/790/930/721/360/840/320/64
Acute myocardial infarctionCardiac disorders0/790/930/720/360/840/321/64
ConstipationGastrointestinal disorders0/790/930/720/360/840/321/64
Most frequent other events
Showing 10 of 30
Most frequent other events
EventInduction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QDOLE Period: Placebo QD -> Ritlecitinib 50 mg QDOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QDOLE Period: Placebo QD -> Brepocitinib 30 mg QDOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD
SARS-CoV-2 test positiveInvestigations3/796/931/726/364/844/328/64
Abdominal painGastrointestinal disorders1/792/934/724/365/844/326/64
Crohn's diseaseGastrointestinal disorders4/792/932/724/369/842/324/64
InsomniaPsychiatric disorders0/790/930/724/360/841/320/64
AcneSkin and subcutaneous tissue disorders0/791/934/724/361/841/322/64
AnaemiaBlood and lymphatic system disorders0/790/930/723/360/842/322/64
TinnitusEar and labyrinth disorders0/790/930/723/361/840/320/64
FatigueGeneral disorders0/790/930/723/362/841/320/64
PyrexiaGeneral disorders0/790/930/723/362/841/323/64
GastroenteritisInfections and infestations0/790/930/723/360/840/321/64

Baseline characteristics

The full analysis set (FAS) included all randomized participants who received at least one dose of the randomized investigational drug (ritlecitinib, brepocitinib, or placebo). Participants who received placebo in induction period were analyzed as a single reporting group.

Age, Continuous
Age, Continuous(Years)Induction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QDTotal
Mean36.1 ± 13.0334.6 ± 10.6436.5 ± 12.7035.6 ± 12.05
Sex: Female, Male
Sex: Female, Male(Participants)Induction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QDTotal
Female374129107
Male425243137
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Induction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QDTotal
Hispanic or Latino2114
Not Hispanic or Latino759169235
Unknown or Not Reported2125
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Induction Period: Placebo QDInduction Period: Ritlecitinib 200 mg/50 mg QDInduction Period: Brepocitinib 60 mg QDTotal
American Indian or Alaska Native0000
Asian56718
Native Hawaiian or Other Pacific Islander0000
Black or African American0022
White718461216
More than one race1113
Unknown or Not Reported2215
08

Study locations

195 sites
  • Dothan Surgery Center
    Dothan, Alabama 36301, United States
  • Gut P.C., dba Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Brighton Surgical Center
    Beverly Hills, California 90210, United States
  • Entertainment Medical Group
    Los Angeles, California 90036, United States
  • Gastrointestinal Biosciences Clinical Trials, LLC
    Los Angeles, California 90067, United States
  • Stanford Medicine Outpatient Center - Digestive Health Center
    Redwood City, California 94063, United States
  • Front Range Endoscopy Center
    Colorado Springs, Colorado 80903, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Gastro Florida
    Clearwater, Florida 33756-3839, United States
  • Gastro Florida
    Clearwater, Florida 33756, United States
  • West Coast Endoscopy Center
    Clearwater, Florida 33756, United States
  • Gastro Florida
    Clearwater, Florida 33762, United States
  • UF Health Jacksonville - Gastroenterology Emerson
    Jacksonville, Florida 32207, United States
  • Millenia Surgery Center
    Orlando, Florida 32811, United States
  • HMD Research LLC
    Orlando, Florida 32819, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • WestGlen Gastrointestinal Consultants, P.A.
    Shawnee Mission, Kansas 66217, United States
  • Chevy Chase Endoscopy Center
    Chevy Chase, Maryland 20815, United States
  • MGG Group Co., Inc., Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Capitol Research
    Rockville, Maryland 20850, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Mass Eye and Ear, Longwood
    Boston, Massachusetts 02115, United States
  • Brigham and Women's Hospital
    Chestnut Hill, Massachusetts 02467, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Eastside Endoscopy Center
    Macomb, Michigan 48044, United States
  • Weill Cornell Medical College - New York Presbyterian Hospital
    New York, New York 10021, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • New York Presbyterian Hospital - Weill Cornell Medical College (Colonoscopy)
    New York, New York 10065, United States
  • New York Presbyterian Hospital - Weill Cornell Medical College Investigational Pharmacy
    New York, New York 10065, United States
  • Weill Cornell Medical College - New York Presbyterian Hospital (Endoscopy Suite)
    New York, New York 10065, United States
  • Weill Cornell Medical College - New York Presbyterian Hospital
    New York, New York 10065, United States
  • DiGiovanna Institute for Medical Education And Research
    North Massapequa, New York 11758-1853, United States
  • UNC Hospitals
    Chapel Hill, North Carolina 27514, United States
  • UNC Hospitals Endoscopy Center at Meadowmont
    Chapel Hill, North Carolina 27517, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • UNC GI Procedures Hillsborough
    Hillsborough, North Carolina 27278, United States
  • Gastroenterology Associates of the Piedmont, PA
    Winston-Salem, North Carolina 27103, United States
  • PMG Research of Winston-Salem, LLC
    Winston-Salem, North Carolina 27103, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Holston Valley Surgery Center
    Kingsport, Tennessee 37660, United States
  • Vanderbilt GI Endoscopy Lab at One Hundred Oaks
    Nashville, Tennessee 37204, United States
  • Vanderbilt Inflammatory Bowel Disease Clinic
    Nashville, Tennessee 37204, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1375, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1610, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-5543, United States
  • Vanderbilt Inflammatory Bowel Disease Clinic
    Nashville, Tennessee 37232, United States
  • First Street Hospital
    Bellaire, Texas 77401, United States
  • First Street Surgical Center
    Bellaire, Texas 77401, United States
  • Hermann Drive Surgical Hospital
    Houston, Texas 77004, United States
  • Pearland Surgery Center
    Houston, Texas 77047, United States
  • GI Alliance
    Southlake, Texas 76092, United States
  • Lonestar Endoscopy, LLP
    Southlake, Texas 76092, United States
  • Texas Digestive Disease Consultants (Administrative, Regulatory)
    Southlake, Texas 76092, United States
  • Gastroenterology Associates of Northern VA
    Fairfax, Virginia 22031, United States
  • Gastroenterology Associates of Northern Virginia
    Fairfax, Virginia 22031, United States
  • Verity Research, Inc.
    Fairfax, Virginia 22031, United States
  • Blue Ridge Medical Research
    Lynchburg, Virginia 24502, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Mater Misericordiae Ltd
    South Brisbane, Queensland 4101, Australia
  • Ballarat Base Hospital
    Ballarat, Victoria 3350, Australia
  • Saint John of God Health Care Inc.
    Subiaco, Western Australia 6008, Australia
  • AKH Wien Universitaetsklinik fuer Innere Medizin III
    Wien, 1090, Austria
  • University Hospital Brussels
    Jette, 1090, Belgium
  • University Hospitals Leuven
    Leuven, 3000, Belgium
  • CHC MontLégia
    Liége, 4000, Belgium
  • Javna zdravstvena ustanova Univerzitetski klinicki centar Republike Srpske,
    Banja Luka, 78000, Bosnia and Herzegovina
  • Winnipeg Regional Health Authority - Health Sciences Centre, Winnipeg
    Winnipeg, Manitoba R3A 1R9, Canada
  • Klinicki Bolnicki centar Split, Zavod za gastroenterologiju
    Split, 21000, Croatia
  • Klinicka bolnica Dubrava Zagreb
    Zagreb, 10000, Croatia
  • Klinicki bolnicki centar Zagreb, Zavod za gastroenterologiju i hepatologiju
    Zagreb, 10000, Croatia
  • Nemocnice Horovice, a.s.
    Horovice, 268 31, Czechia
  • Hepato-Gastroenterologie HK s.r.o.
    Hradec Kralove, 500 12, Czechia
  • Medialpharma s.r.o.
    Hradec Kralove, 500 12, Czechia
  • MUDr. GREGAR s.r.o.
    Olomouc, 77900, Czechia
  • Nemocnice Strakonice, a.s., Interni oddeleni
    Strakonice, 386 01, Czechia
  • Nemocnice Strakonice, a.s.
    Strakonice, 386 29, Czechia
  • LTD "Acad. F. Todua Medical Center - LTD Research Institute of Clinical Medicine"
    Tbilisi, 0112, Georgia
  • The First University Clinic of TSMU
    Tbilisi, 0141, Georgia
  • Institute of Clinical Cardiology, Ltd.
    Tbilisi, 0159, Georgia
  • Paian MED Research GmbH
    Berlin, 10318, Germany
  • Krankenhaus Waldfriede e.V.,
    Berlin, 14163, Germany
  • Universitaetsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Bekes Megyei Kozponti Korhaz, Rethy Pal Tagkorhaz
    Bekescsaba, 5600, Hungary
  • Semmelweis Egyetem, II. Belgyogyaszati Klinika
    Budapest, 1088, Hungary
  • Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak
    Budapest, 1125, Hungary
  • Clinfan Szolgaltato Kft.
    Szekszard, 7100, Hungary
  • IRCCS Saverio de Bellis
    Castellana Grotte, Bari 70013, Italy
  • A.O.Spedali Civili
    Brescia, BS 25123, Italy
  • Univ. "Magna Graecia" di Catanzaro
    Catanzaro, CZ 88100, Italy
  • ASST Monza
    Monza, MB 20090, Italy
  • Istituto Clinico Humanitas IRCCS - Sez. Autonoma di Malattie, Infiammatorie Croniche Intestinali
    Rozzano, Milan 20089, Italy
  • A.O.U. Policlinico G. Martino
    Messina, 98125, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Policlinico Universitario Campus Bio-Medico
    Roma, 00128, Italy
  • Kyungpook National University Hospital
    Daegu, Korea 41944, Korea, Republic of
  • Kyung Hee University Hospital
    Seoul, 02447, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
  • Saint George Hospital University Medical Center
    Achrafieh, Lebanon
  • American University of Beirut Medical Center
    Beirut, Lebanon
  • Ain Wazein Medical Village
    El Chouf, Lebanon

Showing the first 100 of 195 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, Clark JD, Dowty ME, Efremov IV, Flick A, Gerstenberger BS, Gopalsamy A, Hayward MM, Hegen M, Hollingshead BD, Jussif J, Knafels JD, Limburg DC, Lin D, Lin TH, Pierce BS, Saiah E, Sharma R, Symanowicz PT, Telliez JB, Trujillo JI, Vajdos FF, Vincent F, Wan ZK, Xing L, Yang X, Yang X, Zhang L. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018 Oct 11;61(19):8597-8612. doi: 10.1021/acs.jmedchem.8b00917. Epub 2018 Aug 16. PubMed 30113844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Oct 2023, 68 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 68 months is above that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2017
First posted
Jan 10, 2018
StartActual
Feb 2, 2018
Primary completionActual
Oct 19, 2023
CompletionActual
Oct 19, 2023
Results first posted
Oct 30, 2024
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03395184
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 10, 2018
Start date
Feb 2, 2018
Primary completion
Oct 19, 2023
Completion
Oct 19, 2023
Results posted
Oct 30, 2024
Last update
Oct 30, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PF-06651600 · PF-06700841

Start the discussion